NCT04692688 - Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

April 8, 2021

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions

Diabetic RetinopathyDiabetic Macular EdemaNPDR - Non Proliferative Diabetic RetinopathyPDR - Proliferative Diabetic Retinopathy

Interventions

DRUG

APX3330

APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.

DRUG

Placebo

Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.

Trial Locations (24)

11967

Clinical Site 15, Shirley

21740

Clinical Site 14, Hagerstown

28210

Clinical Site 20, Charlotte

33143

Clinical Site 19, Miami

33880

Clinical Site 7, Winter Haven

46290

Clinical Site 6, Carmel

48439

Clinical Site 17, Grand Blanc

57701

Clinical Site 1, Rapid City

76092

Clinical Site 13, Southlake

76104

Clinical Site 10, Fort Worth

77030

Clinical Site 16, Bellaire

78240

Clinical Site 3, San Antonio

78550

Clinical Site 4, McAllen

78624

Clinical Site 23, San Antonio

78705

Clinical Site 18, Austin

84010

Clinical Site 21, Ogden

85014

Clinical Site 9, Phoenix

87113

Clinical Site 12, Albuquerque

91607

Clinical Site 5, Beverly Hills

92260

Clinical Site 11, Palm Desert

93309

Clinical Site 8, Bakersfield

94598

Clinical Site 24, Walnut Creek

95825

Clinical Site 2, Sacramento

01107

Clinical Site 22, Springfield